Bariatric Surgery Candidate, Cholecystectomy
Conditions
Brief summary
Determination of accuracy With Edmond (reg) expiratory propofol measurement Device, compared With concommitant plasma samples of propofol
Detailed description
Edmon (trade mark) is a New Device from BBraun, measuring the expiratory concentration of propofol in anaesthetized patients. The investigators will test the accuracy and stability of such measurements in comparison With plasma propofol Levels. The investigators will test during target Control infusion (Marsh model) and assumed stable plasma Levels. Plasma samples of propofol will be taken for comparison With exhaled propofol.
Interventions
DEVICEEdmon (reg), BBraun
exhaled propofol will be compared With plasma propofol values
Sponsors
Oslo University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
One Group of morbidly obese patients for bariatric surgery One Group of normal weight cholecystectomy
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* • Patients admitted to Oslo University Hospital, scheduled for elective laparoscopic bariatric surgery or elective laparoscopic cholecystectomy. * Both genders. * Age 18-60 years, both inclusive. * BMI ≥ 20 kg/m2, 10 patients with BMI 20-30, and 10 patients with BMI \> 40 * ASA classification I-III
Exclusion criteria
* • Known hypersensitivity or other contraindication to propofol administered as Target Controlled Infusion. * Patients which during a preoperative visit are deemed not to tolerate propofol bolus or infusion as administered by Target Controlled Infusion. * Ongoing neuroleptic medication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| exhaled propofol concentration | start of anaesthesia to end of anaesthesia, 2-3 hours in total | parts per billion |
| propofol plasma concentration | 4-6 samples in the period between start and end of anaesthesia | microg pr ml |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| calculated effect site concentration | from start of anaesthesia until end of anaesthesia, 1-3 hours in total | Marsh model, microg pr ml |
| calculated plasma concentration | From start of anaesthesia until end of anaesthesia, 1-3 hrs in total | Marsh model prediction, microg pr ml |
| EEG Power distribution | from start of anaesthesia until end of anaesthesia, 1-3 hours in total | % representation relative Power of Alpha, Beta, Theta, Gamma band |
| EEG Power spectrum | f | Spectral edge value (Hz) |
| BIS | from start of anaesthesia until end of anaestheisa, 1-3 hours in total | Bispectral index value, score = 0-100 |
Countries
Norway
Outcome results
None listed